Publication details

Nová – přímá perorální antikoagulancia: aktuální přehled

Title in English New – direct oral anticoagulants: actual review
Authors

MICHALCOVÁ Jana PENKA Miroslav BULIKOVÁ Alena ZAVŘELOVÁ Jiřina ŠTĚPAŘOVÁ Andrea

Year of publication 2016
Type Article in Periodical
Magazine / Source Vnitřní lékařství
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords apixaban; dabigatran; DOAC; NOAC; rivaroxaban
Description In recent years the options of anticoagulant/antithrombotic therapy have extended with new – direct oral anticoagulants, comprising direct thrombin inhibitors (dabigatran etexilate) and direct factor Xa inhibitors (rivaroxaban, apixaban). These agents represent another progress towards “the ideal antithrombotic drug“, and thus towards a safe and effective antithrombotic therapy. The following article provides actual review and recommendations for clinical practice, including laboratory assessment and management of emergency situations. The approval of idarucizumab as a specific antidote for dabigatran has marked an important step in safety of this treatment.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info

By clicking “Accept Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Settings

Necessary Only Accept Cookies